๐Ÿ”ฅEarly Investing’s recent pick is 50% Funded: Phoenix PharmaLabs

Click to rate this post!
[Total: 0 Your Rating: 0]

50% Funded: Phoenix PharmaLabs

$605k+ Raised | 776 investors | $99 min.

Phoenix PharmaLabs (PPL) aims to disrupt the $35Bn opioid market with non-addictive drugs that kill pain, not people, and could solve the opioid crisis. PPL is a preclinical drug discovery company dedicated to the development of potent, safe, non-addictive treatments for pain and addiction.
Deal Highlights
Recommended by Early Investing, a top investment newsletter
Received ~$3M in grants from the US Army and the National Institute of Health
Demonstrated 10x potency of morphine in preclinical animal studies of lead drug
Raising 2nd round of funding following a $1.1M oversubscribed round on Netcapital in 2019
Entering a $35Bn market
Developing potential treatments for acute pain, chronic pain, and addiction

Why Others Invested

What motivated your investment?
“Combatting the opioid epidemic through non-addictive painkillers. Being a service member myself, I know of fellow veterans, whether colleagues or close friends, who suffer from mental health problems or physical [problems] or even both. I feel convinced knowing the Army has provided Phoenix with a grant as well as the National Institute of Drug Abuse.”

What motivated your investment?
“I am a retired psychiatrist who has worked with those who use or are addicted to opioids and who have lost one or many more friends or family as a consequence of unintended opioid overdoses attributed to black market sources of either heroin or fetanyl. A non-addicting opioid offered legally on the market would put an end to such risks for those who have acute or chronic pain conditions.”


Join Our Newsletter



By Registering, you agree that you've read and accepted our disclaimer, you're at least 18 years old, you consent to the terms presented on the disclaimer, and to receive notifications from us.